How much funding has Oak Hill Biosciences raised?

Oak Hill Biosciences has raised $32.5M in total funding, most recently a Series A round.

When was Oak Hill Biosciences founded?

Oak Hill Biosciences was founded in 2024.

Where is Oak Hill Biosciences headquartered?

Oak Hill Biosciences is headquartered in Cambridge, United States.

What industry is Oak Hill Biosciences in?

Oak Hill Biosciences operates in Biotech.

Oak Hill Biosciences

Q: Who are Oak Hill Biosciences's investors?

Oak Hill Biosciences's investors include Balyasny Asset Management, Janus Henderson Investors, venBIO Partners.

formerly Oak Hill Bio

Advancing Rare Disease Therapies Across the Finish Line

Cambridge, United States · Founded 2024 · $32.5M raised

Biotech

Headquarters: Cambridge
Founded: 2024
Business Model: B2B
Website: oakhillbio.com

Total Funding: $32.5M
Last Round: $32.5M Series AJun 2026
Rounds: 1

About

Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops outstanding rare-disease drug candidates deprioritized by large pharmaceutical companies. Its lead asset, rugonersen (OHB-724), is a Phase 3-ready antisense oligonucleotide licensed from Roche for Angelman syndrome, a rare neurodevelopmental disease with significant unmet need.

Summary

Oak Hill Biosciences is a Biotech company based in Cambridge, United States, founded in 2024. It has raised $32.5M in total across 1 round, most recently a $32.5M Series A round in Jun 2026. Investors include Balyasny Asset Management, Janus Henderson Investors and venBIO Partners.